In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Voyager Therapeutics (NASDAQ:VYGR) over the past three months, with a range of price targets from $7 to $30. The average price target has decreased by 9.57% to $20.5. Voyager Therapeutics is a gene therapy company with a strong revenue growth rate and prudent debt management.
October 16, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Voyager Therapeutics has received mixed analyst ratings, with a decrease in the average price target to $20.5. Analysts have set a high target of $30 and a low of $7, reflecting diverse expectations. The company's strong revenue growth and prudent debt management are positive indicators.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty about Voyager Therapeutics' short-term stock performance. However, the company's strong revenue growth and prudent debt management are positive factors that could support the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100